

# Faculty

## Chairs:

**Professor Jean-Pierre Bassand**  
University Hospital Jean Minjot  
Besançon, France

**Professor Keith Fox**  
University of Edinburgh  
Edinburgh, Scotland, UK

## Speakers:

**Dr Charles Esmon**  
Howard Hughes Medical Institute  
University of Oklahoma Health Science Center  
Oklahoma City, OK, USA

**Dr Alexander GG Turpie**  
McMaster University and Hamilton Health Sciences  
Hamilton, Ontario, Canada

**Professor Jean-Pierre Bassand**  
University Hospital Jean Minjot  
Besançon, France

**Professor Freek Verheugt**  
Onze Lieve Vrouwe Gasthuis  
Amsterdam, The Netherlands

For further information please visit the Bayer Schering Pharma exhibition booth,  
Exhibition Hall, Zone 3, Booth No E100

## Organized by Bayer Schering Pharma AG

The marketing authorization for rivaroxaban may vary from country to country. In Spain, rivaroxaban is currently approved for prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery and is not approved for arterial indications.



BHCO1967/0409

# Thrombosis Management in Cardiology:

## The relevance of direct Factor Xa inhibition

Chaired by Jean-Pierre Bassand and Keith Fox

**Monday 31 August 2009, 18:30–20:00**

Room Sofia, Zone 1, Fira Gran Via, Barcelona, Spain

A Satellite Symposium organized by Bayer Schering Pharma AG  
at the ESC Congress 2009  
Barcelona, Spain  
29 August–2 September 2009



# Chairmen's Welcome

Dear Colleagues,

Anticoagulant therapy plays a critical role in the overall management of a range of cardiovascular disorders. Direct Factor Xa inhibition provides effective prophylaxis against venous thromboembolism (VTE) after elective hip and knee replacement surgery in adult patients. The potential clinical benefit of direct Factor Xa inhibition is being investigated in a series of cardiovascular indications such as stroke prevention in patients with atrial fibrillation and secondary prevention of further events in patients with acute coronary syndrome.

We are pleased to host this Satellite Symposium at the ESC Congress 2009, and invite you to attend presentations that review both the current strategies for thrombosis management in cardiology, and the prospects for improved management strategies with the introduction of novel anticoagulants.

To set the scene, Dr Charles Esmon will review the rationale for Factor Xa inhibition in thrombosis management. Dr Alexander GG Turpie will then examine the evidence from recent trials of novel oral anticoagulants for VTE prevention after elective hip and knee replacement surgery. This presentation will include the results from the extensive phase III RECORD programme, which compared the novel, oral, direct Factor Xa inhibitor rivaroxaban with enoxaparin.

Chairman Professor Jean-Pierre Bassand will focus on issues of stroke prevention strategies in patients with atrial fibrillation. He will present data from atrial fibrillation registries and review how this information can better inform clinical practice. Finally, Professor Freek Verheugt will provide an overview of the latest clinical results of new anticoagulants in cardiology, and the potential clinical benefits for patients with acute coronary syndrome.

We hope that you will be able to join us for what promises to be a very informative and exciting session.

Kind regards,



Jean-Pierre Bassand



Keith Fox

# Thrombosis Management in Cardiology:

## The relevance of direct Factor Xa inhibition

Chaired by Jean-Pierre Bassand and Keith Fox

**Monday 31 August 2009, 18:30–20:00**

Room Sofia, Zone 1, Fira Gran Via, Barcelona, Spain

A Satellite Symposium organized by Bayer Schering Pharma AG at the ESC Congress 2009, 29 August–2 September 2009

- |              |   |
|--------------|---|
| <b>18:30</b> | <b>Welcome and introduction</b><br>Jean-Pierre Bassand, France  |
| <b>18:40</b> | <b>Growing evidence for the effectiveness of Factor Xa inhibition</b><br>Charles Esmon, USA   |
| <b>18:55</b> | <b>Factor Xa inhibition and the prevention of venous thromboembolism</b><br>Alexander GG Turpie, Canada   |
| <b>19:10</b> | <b>Anticoagulant issues in routine clinical care of patients with atrial fibrillation: Lessons from registries</b><br>Jean-Pierre Bassand, France |
| <b>19:25</b> | <b>Prospects for improving thrombosis management strategies in cardiology</b><br>Freek Verheugt, The Netherlands                                  |
| <b>19:40</b> | <b>Panel and audience discussion</b>  |
| <b>19:55</b> | <b>Summary and close</b><br>Keith Fox, UK   |

